NCT02192463已完成1 期
Relative Bioavailability of Different Oral Viramune Extended Release Formulations Containing 300 mg or 400 mg Compared to 200 mg or 400 mg as One or Two 200 mg IR Tablets Following Administration in Healthy Male Volunteers - an Openlabel, Non-randomized, Parallel Group Study
适应症
干预措施
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 204
- 主要终点
- AUC0-∞ (area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity)
研究概览
简要总结
Study to determine the relative bioavailability of different oral Viramune Extended Release (ER) formulations compared to Viramune® Immediate Release (IR) tablet
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 50 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •Healthy males according to the following criteria based upon a complete medical history, including the physical examination, vital signs (Blood Pressure (BP), Pulse Rate (PR)), 12-lead electrocardiogram (ECG), clinical laboratory
- •Age ≥18 and Age ≤50 years
- •Body Mass Index (BMI) ≥18.5 and BMI ≤29.9 kg/m2
- •Signed and dated written informed consent prior to admission to the study in accordance with Good Clinical Practice and the local legislation
排除标准
- •Any finding of the medical examination (including BP, PR and ECG) deviating from normal and of clinical relevance
- •Any evidence of a clinically relevant concomitant disease
- •Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders of clinical relevance
- •Surgery of the gastrointestinal tract (except appendectomy and herniotomy)
- •Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders
- •History of relevant orthostatic hypotension, fainting spells or blackouts
- •Chronic or relevant acute infections
- •History of relevant allergy/hypersensitivity (including allergy to drug or its excipients)
- •Intake of drugs with a long half-life (> 24 hours) within at least one month or less than 10 half-lives of the respective drug prior to administration or during the trial
- •Use of drugs which might reasonably influence the results of the trial based on the knowledge at the time of protocol preparation within 10 days prior to administration or during the trial
- •Participation in another trial with an investigational drug within two months prior to administration or during the trial
- •Smoker (> 10 cigarettes or > 3 cigars or > 3 pipes/day)
- •Inability to refrain from smoking on trial days
- •Alcohol abuse (more than 60 g/day)
- •Drug abuse
- •Blood donation (more than 100 mL within four weeks prior to administration or during the trial)
- •Excessive physical activities (within one week prior to administration or during the trial)
- •Any laboratory value outside the reference range that is of clinical relevance
- •Inability to comply with dietary regimen of trial site
- •A marked baseline prolongation of QT/QTc interval (e.g., repeated demonstration of a corrected QT interval (QTc) >450 ms)
- •A history of additional risk factors for torsade de pointes (e.g., heart failure, hypokalemia, family history of Long QT Syndrome)
- •History of disease which affects the present situation
研究组 & 干预措施
NVP ER 400 mg (KCR 40%) Slow Release
Experimental
干预措施: NVP ER 400 mg (KCR 40%) Slow Release (Drug)
NVP ER 400 mg (ECR 20%) Fast Release
Experimental
干预措施: NVP ER 400 mg (ECR 20%) Fast Release (Drug)
Nevirapine (NVP) ER 300 mg (KCR 20%) Medium Release
Experimental
干预措施: NVP ER 300 mg (KCR 20%) Medium Release (Drug)
NVP ER 300 mg (KCR 25%) Medium Release
Experimental
干预措施: NVP ER 300 mg (KCR 25%) Medium Release (Drug)
NVP ER 300 mg (KCR 30%) Slow Release
Experimental
干预措施: NVP ER 300 mg (KCR 30%) Slow Release (Drug)
NVP ER 400 mg (KCR 25%) Medium Release
Experimental
干预措施: NVP ER 400 mg (KCR 25%) Medium Release (Drug)
NVP ER 300 mg (KCR 40%) Slow Release
Experimental
干预措施: NVP ER 300 mg (KCR 40%) Slow Release (Drug)
NVP ER 300 mg (ECR 20%) Fast Release
Experimental
干预措施: NVP ER 300 mg (ECR 20%) Fast Release (Drug)
NVP ER 400 mg (KCR 20%) Medium Release
Experimental
干预措施: NVP ER 400 mg (KCR 20%) Medium Release (Drug)
NVP ER 400 mg (KCR 30%) Slow Release
Experimental
干预措施: NVP ER 400 mg (KCR 30%) Slow Release (Drug)
Nevirapine IR 1 tablet
Active Comparator
干预措施: Nevirapine immediate release (IR) 200 mg (Drug)
Nevirapine IR 2 tablets
Active Comparator
干预措施: Nevirapine immediate release (IR) 200 mg (Drug)
结局指标
主要结局
AUC0-∞ (area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity)
时间窗: up to 144 hours post-dose
Cmax (maximum measured concentration of the analyte in plasma)
时间窗: up to 144 hours post-dose
C24 (measured concentration of the analyte in plasma at 24 hours post-dose)
时间窗: 24 hours post-dose
次要结局
- Cmax/C24 ratio(up to 144 hours post-dose)
- AUC0-tz (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the time of the last quantifiable data point)(up to 144 hours post-dose)
- λz (terminal rate constant in plasma)(up to 144 hours post-dose)
- t1/2 (terminal half-life of the analyte in plasma)(up to 144 hours post-dose)
- MRTpo (mean residence time of the analyte in the body after po administration) CL/F (apparent clearance of the analyte in the plasma after extravascular administration)(up to 144 hours post-dose)
- Vz/F (apparent volume of distribution during the terminal phase λz following an extravascular dose)(up to 144 hours post-dose)
- ka (absorption rate constant)(up to 144 hours post-dose)
- Number of patients with adverse events(up to 36 days)
- Assessment of tolerability by investigator on a 4-point scale(within 8 days after last trial procedure)
- tmax (time from dosing to the maximum concentration of the analyte in plasma)(up to 144 hours post-dose)
研究者
相似试验
已完成
1 期
Relative Bioavailability and Tolerability of Various Experimental Formulations of BIBV 308 SE in Healthy SubjectsHealthyNCT02223000Boehringer Ingelheim9
撤回
1 期
A Phase I Study to Test Alternate Oral Formulations vs the Current Tablet Formulation of LapatinibHealthy SubjectsNCT00513253GlaxoSmithKline
已完成
1 期
A Research Study Comparing Active Drug in the Blood in Healthy Participants Following Dosing of the Current and a New Formulation (C) Semaglutide TabletsHealthy VolunteersType 2 DiabetesNCT04109508Novo Nordisk A/S278
已完成
1 期
A Research Study Comparing Active Drug in the Blood in Healthy Participants Following Dosing of the Current and a New Formulation (D) Semaglutide TabletsHealthy VolunteersType 2 DiabetesNCT04097600Novo Nordisk A/S274
已完成
1 期
A Study to Compare How Tamsulosin is Absorbed to the Body After Administration of Two Types of Tamsulosin Formulation Under Fed and Fasted Conditions in Chinese Healthy SubjectsHealthyPharmacokinetics of Tamsulosin HydrochlorideNCT02138773Astellas Pharma China, Inc.80